Dupixent and Cancer: What Are Your Legal Rights and Options?

Were you prescribed Dupixent to treat your eczema? Were you later diagnosed with cancer? If so, you are not alone.

While the drug has shown meaningful results for many patients, serious concerns have emerged regarding a potential link to cancer that some allege was not adequately disclosed by Dupixent manufacturers Regeneron and Sanofi-Aventis. Recently, the drug makers have faced a heavy number of lawsuits alleging that they knew or should have known about the possible cancer risks linked to the drug – but prioritized profits over the safety of patients.

If you, or a loved one, have been diagnosed with cancer after using Dupixent, you may have legal options.

What Is Dupixent?

Dupixent is a biologic injectable drug prescribed to treat atopic dermatitis (eczema), asthma, and other inflammatory diseases. It works by blocking certain proteins responsible for inflammation. Dupixent is administered by injection every two to four weeks and is often prescribed when other treatments have failed.

Dupixent is the brand name for the drug dupilumab. Because it has offered relief when topical treatments were not effective, it is a commonly prescribed medication for managing skin and respiratory conditions. However, one study cited in the Journal of the American Academy of Dermatology concluded that dupilumab was associated with an increased risk of CTCL (Cutaneous T-Cell Lymphoma) in patients with atopic dermatitis. Researchers found that Dupixent users had a roughly 4x greater risk of developing CTCL than those who did not use the drug.

Who Uses Dupixent?

Dupixent is commonly prescribed for:

• Individuals with moderate to severe eczema, such as atopic dermatitis
• Patients managing moderate to severe asthma who need ongoing maintenance treatment
• People affected by chronic rhinosinusitis with nasal polyps, including cases involving allergic fungal rhinosinusitis
• Those diagnosed with eosinophilic esophagitis or similar inflammatory disorders linked to immune system activity

Types of Cancer Linked to the Use of Dupixent

Emerging research and adverse event reports have raised concerns about a potential association between Dupixent use and the development of certain cancers, including:

• Cutaneous T-Cell Lymphoma (CTCL): CTCL is a form of non-Hodgkin lymphoma affecting the skin, with cases reported in patients who were initially misdiagnosed with eczema and subsequently treated with Dupixent. Many allege that Dupixent suppressed the inflammation without addressing the underlying disease which allowed the CTCL to progress unchecked. Others allege that the drug triggered the CTCL.
• Lymphoma: Broader lymphatic system cancers have been reported in a subset of Dupixent users, raising questions about the drug’s effect on immune regulation.
• Skin Cancer: Some patients have reported the development of malignant skin conditions following prolonged Dupixent use.
• Other Malignancies: Concerns have been raised regarding the drug’s immunomodulatory mechanism and its potential to suppress the body’s natural cancer surveillance functions, possibly increasing vulnerability to other cancers.

Current Litigation About Dupixent

Dupixent lawsuits claim that the manufacturers of this medication failed to adequately warn users about the possible linkages to cancer. They also point to the fact that because CTCL symptoms resemble severe eczema symptoms, the lack of warning by the manufacturers also may have delayed the cancer diagnoses of some patients, which allowed the disease to worsen undetected.

In March 2026, a motion was filed to transfer and consolidate Dupixent cancer cases in federal court in Georgia as part of Multi-District Litigation (MDL). Multi-District Litigation is how the court system handles situations where large numbers of people are harmed by the same product. All of the cases are managed together by one federal judge, which keeps things efficient and consistent. Your case is still yours – you’re just part of a larger, coordinated effort to hold these companies accountable.

Do You Have a Dupixent Cancer Case?

You may be eligible to pursue a claim if you were prescribed and used Dupixent and subsequently:

• Received a cancer diagnosis – including lymphoma, cutaneous T-cell lymphoma, or another malignancy – during or following your use of Dupixent
• Your diagnosis required surgery, chemotherapy, radiation, or other significant medical treatment
• You and your prescribing physician were not adequately informed of the potential cancer risk prior to treatment

What Types of Compensation Can You Seek?

You could be owed these and other types of compensation:

• Past and current medical bills
• Medical treatment needed in the future
• Prescription drug costs
• Pain and suffering
• Wages lost due to missed work
• Emotional trauma

We Can Help You Seek Justice – Free Case Evaluation

If you, or a loved one, have been diagnosed with cancer after taking Dupixent, our legal team is here to help. We offer a free, no-obligation case evaluation to help you better understand your options.

The Law Offices of James Scott Farrin has helped 78,000+ injured people fight for justice since 1997. We’ve recovered more than $2 billion in total compensation for our clients, and counting.¹

Do not wait – time limits apply to your claim. Call us today at 1-866-900-7078 or contact us online to tell us your story.

Text Us

The Law Offices of James Scott Farrin consults with a national network of attorneys on product liability, defective drugs, and defective products cases in an attempt to provide the best representation we can for our clients. Depending on the details of your case, our firm may refer your matter to another law firm with which we associate. We will only do this if we believe it is in your best interests and if you agree.